Shares of Illumina (ILMN) were lower Tuesday after the biotech firm cut its third-quarter sales expectations to $607 million, that's down more than 3% from the midpoint of its prior guidance. Illumina also said it expects to see a fall in sales of its sequencing instruments. Analysts with Cantor Fitzgerald wrote Tuesday that Illumina's troubles are "largely company-specific" and that Cantor Fitzgerald is still positive on industry peers such as Pacific Biosciences (PACB) .
More from Video
Amid the Selling, Here's the Big Question Now
How quickly do we find support, is what we'll want to know now, as the correction is occurring while economic optimism builds.
One Tweet Pulls the Rug Out From Under the Indexes
Despite the president's promise of no stimulus until after Nov. 3, there are no signs yet that this is the sort of correlated selling that leads to a deep correction.
A Technical Look at the New Dow Jones Industrial Average
Salesforce, Amgen and Honeywell will give a lift to the DJIA going forward.
Conagra Brands Looks Tastier After Its Upgrade to Buy
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Biogen Bulls Get a Lift From Quant Upgrade and Strengthening Charts
Breaking down an approach to the long side of this biotech stock.